{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:59:25Z","timestamp":1790229565490,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Circulating tumor DNA (ctDNA) measures cancer-specific genetic material migrated from a tumor to a patient's bloodstream. Limited research exists aggregating data on ctDNA as a measure of recurrence, treatment success, and survival in patients with melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>The authors aim to evaluate evidence for ctDNA as a measurement of recurrence and survival, and how those results differ by tumor grade and measurement time point in cutaneous melanoma treated with dermatologic surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>An OVID Medline search and manual filtering resulted in six studies meeting the inclusion criteria: evaluating survival and\/or disease recurrence by ctDNA measurement in patients with cutaneous melanoma who had undergone dermatologic surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Sequencing methods varied: some studies analyzed known gene mutations and others developed individual tumor assays. Individual assays provide more information but are less practical to perform. Significant relationships between postoperative ctDNA level and disease recurrence and survival were found in multiple studies. The most represented stages of melanoma included were II and III. All studies measured postoperative ctDNA, but at unique time points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>ctDNA measurement may be a useful tool in measuring treatment efficacy and disease recurrence in patients with cutaneous melanoma treated with dermatologic surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dss.0000000000005100","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:00:11Z","timestamp":1775242811000},"page":"925-928","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Circulating Tumor DNA as a Predictor of Recurrence and Survival in Cutaneous Melanoma Treated With Dermatologic Surgery: A Review"],"prefix":"10.1097","volume":"52","author":[{"given":"Sabine L.","family":"Abukhadra","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California Davis School of Medicine, Sacramento, California"},{"name":"Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Eisen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California Davis School of Medicine, Sacramento, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"R1-20260924","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-018-0398-x","article-title":"Monitoring melanoma using circulating free DNA","volume":"20","author":"Diefenbach","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"R2-20260924","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/PO.19.00174","article-title":"Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma","volume":"4","author":"Braune","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"R3-20260924","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R4-20260924","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S2468-1253(23)00146-2","article-title":"Clinical application of circulating tumour DNA in colorectal cancer","volume":"8","author":"Loft","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R5-20260924","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol"},{"key":"R6-20260924","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease - latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R7-20260924","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1158\/0008-5472.CAN-21-1718","article-title":"Current and future clinical applications of ctDNA in immuno-oncology","volume":"82","author":"Stadler","year":"2022","journal-title":"Cancer Res"},{"key":"R8-20260924","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1245\/s10434-025-17194-z","article-title":"Circulating tumor DNA in high-risk stage II\/III cutaneous melanoma: a feasibility study","volume":"32","author":"Rhodin","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"R9-20260924","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CMR.0000000000001041","article-title":"Circulating tumor DNA predicts tumor progression and poor survival in patients with stage III melanoma","volume":"35","author":"Palacios-Diaz","year":"2025","journal-title":"Melanoma Res"},{"key":"R10-20260924","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/annonc\/mdx717","article-title":"Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma","volume":"29","author":"Lee","year":"2018","journal-title":"Ann Oncol"},{"key":"R11-20260924","doi-asserted-by":"crossref","first-page":"873728","DOI":"10.3389\/fmed.2022.873728","article-title":"Current trends in circulating biomarkers for melanoma detection","volume":"9","author":"Huang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R12-20260924","doi-asserted-by":"crossref","first-page":"9562","DOI":"10.1200\/JCO.2023.41.16_suppl.9562","article-title":"Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma","volume":"41","author":"Gebhardt","year":"2023","journal-title":"J Clin Oncol"},{"key":"R13-20260924","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.3390\/cancers14174158","article-title":"The prognostic value of a single, randomly timed circulating tumor DNA measurement in patients with metastatic melanoma","volume":"14","author":"Boerlin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R14-20260924","doi-asserted-by":"crossref","first-page":"e21564","DOI":"10.1200\/JCO.2024.42.16_suppl.e21564","article-title":"Detection of molecular residual disease in stage II and III melanoma utilizing circulating tumor DNA","volume":"42","author":"Chen","year":"2024","journal-title":"J Clin Oncol"},{"key":"R15-20260924","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.18632\/oncotarget.5788","article-title":"Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma","volume":"6","author":"Gray","year":"2015","journal-title":"Oncotarget"},{"key":"R16-20260924","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40291-021-00559-x","article-title":"Commercial ctDNA assays for minimal residual disease detection of solid tumors","volume":"25","author":"Chen","year":"2021","journal-title":"Mol Diagn Ther"},{"key":"R18-20260924","doi-asserted-by":"crossref","first-page":"103978","DOI":"10.1016\/j.esmoop.2024.103978","article-title":"Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients","volume":"9","author":"Genta","year":"2024","journal-title":"ESMO Open"},{"key":"R20-20260924","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdz048","article-title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","volume":"30","author":"Tan","year":"2019","journal-title":"Ann Oncol"},{"key":"R21-20260924","doi-asserted-by":"crossref","first-page":"100357","DOI":"10.1016\/j.esmoop.2021.100357","article-title":"Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma","volume":"7","author":"Gouda","year":"2022","journal-title":"ESMO Open"},{"key":"R22-20260924","doi-asserted-by":"crossref","first-page":"e70313","DOI":"10.1002\/cam4.70313","article-title":"Predictive significance of combined plasmatic detection of BRAF mutations and S100B tumor marker in early-stage malignant melanoma","volume":"13","author":"Polivka","year":"2024","journal-title":"Cancer Med"},{"key":"R23-20260924","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/CMR.0000000000000892","article-title":"Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma","volume":"33","author":"Brunsgaard","year":"2023","journal-title":"Melanoma Res"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:00:45Z","timestamp":1790226045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000005100","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}